Suchergebnisse - (Person:"Liu, Binliang")

PubPharm (7)

1

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer : Novel prognostic indexes based on ctDNA

enthalten in: Breast (Edinburgh, Scotland) | 2022

von Liu, B. | Hu, Z. | Ran, J. | +4

2

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients

enthalten in: Cancer medicine | 2022

von Liu, B. | Yi, Z. | Guan, Y. | +10

3

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC

enthalten in: Frontiers in endocrinology | 2022

von Tang, Y. | Li, J. | Liu, B. | +3

4

The molecular tumor burden index as a response evaluation criterion in breast cancer

enthalten in: Signal transduction and targeted therapy | 2021

von Yi, Z. | Ma, F. | Rong, G. | +10

5

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Yi, Z. | Liu, B. | Sun, X. | +10

6

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Guan, X. | Liu, B. | Niu, Y. | +9

7

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

enthalten in: Scientific reports | 2017

von Yi, Z. | Ma, F. | Li, C. | +9

1
[1]